ZIVO Bioscience, Inc. (ZIVO)
OTCMKTS · Delayed Price · Currency is USD
3.112
-0.488 (-13.54%)
Sep 8, 2026, 3:29 PM EST
ZIVO Bioscience Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 0.06 | 1.54 | 0.27 | 1.8 | 8.9 | 0.14 |
Cash & Short-Term Investments | 0.06 | 1.54 | 0.27 | 1.8 | 8.9 | 0.14 |
Cash Growth | -64.10% | 462.16% | -84.75% | -79.79% | 6357.09% | -60.17% |
Receivables | - | 0 | 0 | - | - | - |
Prepaid Expenses | 0.22 | 0.09 | 0.15 | 0.1 | 0.06 | 0.03 |
Total Current Assets | 0.28 | 1.64 | 0.43 | 1.9 | 8.96 | 0.17 |
Property, Plant & Equipment | 0.27 | - | 0.1 | 0.19 | 0.03 | 0.05 |
Other Long-Term Assets | 0.01 | 0.01 | 0.03 | 0.03 | 0 | 0 |
Total Assets | 0.56 | 1.64 | 0.56 | 2.12 | 8.99 | 0.22 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 1.33 | 0.74 | 1.17 | 0.49 | 0.65 | 1.56 |
Accrued Expenses | 1.69 | 1.16 | 1.25 | 0.5 | 0.56 | 2.68 |
Short-Term Debt | 0.15 | - | - | - | - | 0.01 |
Current Portion of Long-Term Debt | 0.38 | 0.14 | 0.24 | 0.24 | 0.24 | 5.18 |
Current Portion of Leases | 0.07 | - | 0.11 | 0.1 | 0.02 | 0.03 |
Current Unearned Revenue | - | - | - | 0.7 | 1.48 | 1.94 |
Total Current Liabilities | 3.61 | 2.04 | 2.76 | 2.03 | 2.95 | 11.39 |
Long-Term Debt | 0.01 | 0.12 | - | - | - | 0.12 |
Long-Term Leases | 0.22 | - | - | 0.11 | - | 0.02 |
Total Liabilities | 3.85 | 2.16 | 2.76 | 2.13 | 2.95 | 11.53 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
Additional Paid-In Capital | 140.56 | 136.45 | 121.37 | 115.79 | 113.09 | 87.75 |
Retained Earnings | -143.85 | -136.97 | -123.58 | -115.8 | -107.06 | -99.06 |
Shareholders' Equity | -3.29 | -0.51 | -2.21 | -0.01 | 6.04 | -11.31 |
Total Liabilities & Equity | 0.56 | 1.64 | 0.56 | 2.12 | 8.99 | 0.22 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 0.82 | 0.25 | 0.35 | 0.45 | 0.26 | 5.36 |
Net Cash (Debt) | -0.76 | 1.29 | -0.07 | 1.35 | 8.65 | -5.22 |
Net Cash Growth | - | - | - | -84.34% | - | - |
Net Cash Per Share | -0.20 | 0.41 | -0.04 | 0.86 | 6.80 | -6.17 |
Filing Date Shares Outstanding | 3.89 | 3.76 | 2.78 | 1.57 | 1.57 | 0.87 |
Total Common Shares Outstanding | 3.83 | 3.62 | 2.38 | 1.57 | 1.57 | 0.83 |
Working Capital | -3.33 | -0.41 | -2.34 | -0.13 | 6.01 | -11.23 |
Book Value Per Share | -0.86 | -0.14 | -0.93 | -0.01 | 3.85 | -13.68 |
Tangible Book Value | -3.29 | -0.51 | -2.21 | -0.01 | 6.04 | -11.31 |
Tangible Book Value Per Share | -0.86 | -0.14 | -0.93 | -0.01 | 3.85 | -13.68 |
Machinery | - | - | - | - | - | 0.1 |